U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

Friday, February 3, 2017

Source: Reuters

The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.

Opdivo, part of a new class of medicines designed to use the body's own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma. 

Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Yervoy, as an initial treatment for lung cancer.

The FDA is slated to decide in May whether to approve rival Merck & Co Inc's combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.

 

 

(Reporting By Deena Beasley; editing by Diane Craft)

View All News »